This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.
Featured news and events
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.
‘Dementia Innovation Readiness Index 2020: 30 Global Cities’ calls strongly for cities to fulfil their commitments under the WHO’s Global action plan on dementia to engage fully with their national dementia plans.